TOMSICEK MICHAEL JOHN 4
4 · CRISPR Therapeutics AG · Filed Oct 6, 2020
Insider Transaction Report
Form 4
TOMSICEK MICHAEL JOHN
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-10-05+11,666→ 11,666 totalExercise: $86.75Exp: 2030-10-05→ Common Shares (11,666 underlying)
Footnotes (1)
- [F1]This option was granted on October 5, 2020 with respect to 11,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 5, 2020.